Erlotinib, in combination with bevacizumab for the second line treatment of non-squamous advanced or metastatic non-small-cell lung cancer after previous platinum containing chemotherapy
- Status:
- Suspended
- Decision:
- Selected
- Process:
- TA
- Referral date:
- 01 November 2008
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
Project Team
- Assessment Group / Evidence Review Group:
- Liverpool Reviews and Implementation Group
- Communications manager:
- Alice Law
- Executive Lead:
- Peter Littlejohns
- Technical Lead:
- Sally Gallaugher
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 2 July 2009 | Appraisal suspended. |
| 6 July 2009 |
The manufacturer of erlotinib has advised us that regulatory approval for this technology is not being sought. The Institute has therefore decided to remove this appraisal from its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes |
For further information on our processes and methods, please see our CHTE processes and methods manual